China National Accord Medicines (SZSE:000028) Total Liabilities : ¥30,106 Mil (As of Mar. 2024)

View and export this data going back to 1993. Start your Free Trial

What is China National Accord Medicines Total Liabilities?

China National Accord Medicines's Total Liabilities for the quarter that ended in Mar. 2024 was ¥30,106 Mil.

China National Accord Medicines's quarterly Total Liabilities declined from Sep. 2023 (¥30,271.05 Mil) to Dec. 2023 (¥26,593.25 Mil) but then increased from Dec. 2023 (¥26,593.25 Mil) to Mar. 2024 (¥30,106.18 Mil).

China National Accord Medicines's annual Total Liabilities declined from Dec. 2021 (¥24,761.47 Mil) to Dec. 2022 (¥23,171.05 Mil) but then increased from Dec. 2022 (¥23,171.05 Mil) to Dec. 2023 (¥26,593.25 Mil).

China National Accord Medicines Total Liabilities Historical Data

The historical data trend for China National Accord Medicines's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China National Accord Medicines Total Liabilities Chart

China National Accord Medicines Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

18,454.86

22,705.91

24,761.47

23,171.05

26,593.25

China National Accord Medicines Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															27,998.28	29,788.76	30,271.05	26,593.25	30,106.18

China National Accord Medicines Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

China National Accord Medicines's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	24338.224	+	(1451.788	+	803.242
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	26,593

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	47571.095	-	20977.84
	=	26,593

China National Accord Medicines's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	27722.116	+	(1642.184	+	741.881
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	30,106

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	51524.997	-	21418.816
	=	30,106

China National Accord Medicines Total Liabilities Related Terms

Thank you for viewing the detailed overview of China National Accord Medicines's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

China National Accord Medicines (SZSE:000028) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » China National Accord Medicines Corp Ltd (SZSE:000028) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

200028:China

Address

No. 15, Ba Gua Si 4th Road, Accord Pharmaceutical Building, Futian District, Guangdong Province, Shenzhen, CHN, 518029

Website

http://www.szaccord.com.cn

China National Accord Medicines Corp Ltd develops and manufactures pharmaceuticals in China. The company engaged in the wholesale of Chinese patent drugs, traditional Chinese medicines, chemical medicine preparations, antibiotics, biochemical drugs and cerebrovascular system drugs. It operates through the following segments: The Head office segment engages in investing and managing the business; The Pharmaceutical Distribution segment engages in the distribution of medicine and pharmaceutical products to customers, including hospitals, other distributors, retail drug stores, and clinics, and Retail pharmacy segment, which is managing the operation of Guoda Pharmacy. It generates maximum revenue from the Pharmaceutical Distribution segment.

China National Accord Medicines (SZSE:000028) Headlines

No Headlines